Prognostic value of plasma Amyloid‐β 42/40 ratio in early and pre‐clinical AD

In 2021 Adacanumab, the first antibody that might potentially treat causal neuropathology associated to Alzheimer’s disease (AD), was approved by the FDA. However, early, most likely pre‐cognitive treatment is required raising a high need for early and low‐invasive diagnostic biomarker. Here, we present plasma Amyoid‐beta (Aβ) measurements in a large longitudinal observational study from the German Center for Neurodegenerative Diseases (DZNE, DZNE‐Longitudinal Cognitive Impairment and Dementia (DELCODE) study).